August 29, 2019
Nippon Kayaku took a pass on the listing of Portrazza (necitumumab), an anti-EGFR antibody it licensed from Eli Lilly, in September as it is “still communicating” with regulators towards its manufacturing and sales, a company spokesperson told Jiho. Lilly obtained...read more